Cancer clinical trials in the region Nouvelle-Aquitaine
409 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Prostate cancer
#NCT05939414
#2022-502956-29-00
Required disease stage
Biochemical recurrence
Metastatic Hormone-sensitive
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Surgery
Radiotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Hormone therapy
7 recruiting sites
Novartis
Phase 3
Lymphoma
#NCT05444712
#2022-501710-62-02
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
Hospices Civils de Lyon
Phase 3
Kidney cancer
#NCT06364631
#2023-503317-29-00
Required histologic types
Clear cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required IMDC scores
0
1 or 2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
36 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Liver and bile duct cancer
#NCT04803994
#2024-512953-26-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced
Required liver status
Unhealthy
Required Child-Pugh scores
A
B
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
10 recruiting sites
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3
Lung cancer
#NCT06627647
#2024-515008-38-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
8 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT06875310
#2024-515698-85-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Lung cancer
#NCT05692999
#2023-503481-23-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
28 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Lung cancer
#NCT06170788
#2023-503376-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06561386
#2024-513682-40-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
NTRK-1/2/3
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
10 recruiting sites
Bristol-Myers Squibb
Phase 3
Lung cancer
#NCT05211895
#2023-506891-28-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Radiotherapy
Excluded genetic anomalies
ALK
EGFR
11 recruiting sites
AstraZeneca